Search results for " BIOMARKERS"

showing 10 items of 365 documents

Decongestion discriminates risk for one-year mortality in patients with improving renal function in acute heart failure

2021

Aims Improving renal function (IRF) is paradoxically associated with worse outcomes in acute heart failure (AHF), but outcomes may differ based on response to decongestion. We explored if the relationship of IRF with mortality in hospitalized AHF patients differs based on successful decongestion.Methods and results We evaluated 760 AHF patients from AKINESIS for the relationship between IRF, change in B-type natriuretic peptide (BNP), and 1-year mortality. IRF was defined as a >= 20% increase in estimated glomerular filtration rate (eGFR) relative to admission. Adequate decongestion was defined as a >= 40% decrease in last measured BNP relative to admission. IRF occurred in 22% of pat…

InotropeMalemedicine.medical_specialtymedicine.drug_classRenal function030204 cardiovascular system & hematologyKidney03 medical and health sciences0302 clinical medicineKidney functionNatriuretic PeptideB&#8208Internal medicineNatriuretic Peptide BrainNatriuretic peptidemedicinetype natriuretic peptideHumansBlood urea nitrogenAgedHeart Failurebusiness.industryAcute heart failure; B-type natriuretic peptide; Congestion; Kidney function; Prognosis; Acute Disease; Aged; Biomarkers; Humans; Kidney; Male; Natriuretic Peptide Brain; Prognosis; Heart FailureHazard ratioBrainAcute heart failuremedicine.diseasePrognosisConfidence interval3. Good healthBlood pressureB-type natriuretic peptideHeart failureAcute DiseaseCardiologyCongestionCardiology and Cardiovascular MedicinebusinessBiomarkersEuropean Journal of Heart Failure
researchProduct

Multibiomarker approach to fipronil exposure in the fish Dicentrarchus labrax under two temperature regimes

2020

12 pages, 5 figures, 3 tables, supplementary data https://doi.org/10.1016/j.aquatox.2019.105378

InsecticidesHealth Toxicology and MutagenesisMetaboliteSea bass010501 environmental sciences01 natural scienceschemistry.chemical_compoundOsmoregulation639LlobarrosClimate changeморские окуниFipronilCYP metabolism0303 health sciencesEnvironmental BiomarkersфипронилPhysiological conditionBiochemical markersTemperaturefood and beveragesLiverокислительный стрессMarcadors bioquímicsOsmoregulationDicentrarchusFipronilOxidation-ReductionбиомаркерыAquatic ScienceBiology03 medical and health sciencesAnimal scienceAnimalsSeawaterPesticidesSea bassEcosystem030304 developmental biology0105 earth and related environmental sciencesfungiEuropean seabassPesticidebiology.organism_classificationизменение климатаGlucosechemistryOxidative stressPyrazolesBassLipid PeroxidationMaltaseWater Pollutants ChemicalBiomarkers
researchProduct

Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collabora…

2018

PubMed: 30270054

International CooperationMÉTODOS EPIDEMIOLÓGICOS030204 cardiovascular system & hematologyNationwide surveyGlobal HealthHealth Services AccessibilityDoenças Cardio e Cérebro-vascularesMOLECULAR-GENETICS0302 clinical medicineRisk FactorsPrevalenceCARDIOVASCULAR RISK-FACTORS030212 general & internal medicineCooperative BehaviorDEFECTIVE APOLIPOPROTEIN B-100GENERAL-POPULATIONeducation.field_of_studymedicine.diagnostic_testAnticholesteremic AgentsFamilial hypercholesterolaemia; FHSC; Primary dyslipidaemia; Anticholesteremic Agents; Biomarkers; Cholesterol LDL; Cooperative Behavior; Genetic Predisposition to Disease; Health Care Surveys; Health Services Accessibility; Healthcare Disparities; Humans; Hyperlipoproteinemia Type II; Phenotype; Predictive Value of Tests; Prevalence; Risk Factors; Treatment Outcome; Blood Component Removal; Global Health; International CooperationEAS Familial Hypercholesterolaemia Studies Collaboration3. Good healthPREVALENCECholesterolPhenotypeTreatment OutcomeBlood Component RemovalCORONARY-ARTERY-DISEASENATIONWIDE SURVEYCardiology and Cardiovascular MedicineFamilial hypercholesterolaemiamedicine.medical_specialtyCardiovascular risk factorsPopulationLDL-RECEPTOR1102 Cardiovascular Medicine And HaematologyLDLHyperlipoproteinemia Type II03 medical and health sciencesPredictive Value of TestsmedicineHumans:Medicine [Science]Genetic Predisposition to DiseasePrimary dyslipidaemiaHealthcare Disparitiesfhsc; familial hypercholesterolaemia; primary dyslipidaemiaeducationGenetic testingGovernmentPublic healthEAS Familial Hypercholesterolaemia Studies Collaboration (FHSC) InvestigatorsSAFEHEART REGISTRY1103 Clinical SciencesFHSCCholesterol LDLCardiovascular System & HematologyFamily medicineHealth Care Surveys3121 General medicine internal medicine and other clinical medicineCardiovascular System & CardiologyBusinessFOLLOW-UPBiomarkers
researchProduct

Corneal Biomechanical Parameters and Central Corneal Thickness in Glaucoma Patients, Glaucoma Suspects, and a Healthy Population

2021

Purpose: To evaluate and compare corneal hysteresis (CH), corneal resistance factor (CRF), and central corneal thickness (CCT), measurements were taken between a healthy population (controls), patients diagnosed with glaucoma (DG), and glaucoma suspect patients due to ocular hypertension (OHT), family history of glaucoma (FHG), or glaucoma-like optic discs (GLD). Additionally, Goldmann-correlated intraocular pressure (IOPg) and corneal-compensated IOP (IOPcc) were compared between the different groups of patients. Methods: In this prospective analytical-observational study, a total of 1065 patients (one eye of each) were recruited to undergo Ocular Response Analyzer (ORA) testing, ultrasoun…

Intraocular pressuremedicine.medical_specialtygenetic structuresOcular hypertensionGlaucomaocular biomarkersMean differenceArticle03 medical and health sciences0302 clinical medicineocular inflammationOphthalmologymedicinecorneal hysteresisbusiness.industryHealthy populationSignificant differenceRGeneral MedicineGlaucoma suspectmedicine.diseaseeye diseasesglaucoma030221 ophthalmology & optometryMedicineAnalysis of variancesense organsbusinesscorneal biomechanics030217 neurology & neurosurgeryJournal of Clinical Medicine
researchProduct

Biochemical biomarkers alterations in Coronavirus Disease 2019 (COVID-19)

2020

Abstract Coronavirus Disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a respiratory disease, which can evolve into multi-organ failure (MOF), leading to death. Several biochemical alterations have been described in COVID-19 patients. To date, many biomarkers reflecting the main pathophysiological characteristics of the disease have been identified and associated with the risk of developing severe disease. Lymphopenia represents the hallmark of the disease, and it can be detected since the early stage of infection. Increased levels of several inflammatory biomarkers, including c-reactive protein, have been found in COVID-19 patients and associ…

Kidney DiseaseClinical BiochemistryMyocardial InfarctionMedicine (miscellaneous)Disease030204 cardiovascular system & hematologySeverity of Illness Index0302 clinical medicineBiomarkers Coronavirus Infection030212 general & internal medicinebiochemical alterationAged 80 and overHealth PolicyLiver DiseasesMusclesLiver DiseaseRespiratory diseaseBlood Coagulation DisordersWater-Electrolyte BalancePathophysiologyC-Reactive ProteinDisease ProgressionCytokinesbiomarkerMuscleKidney DiseasesLiver dysfunctionCoronavirus InfectionsHumanCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Pneumonia Viralmacromolecular substances03 medical and health sciencesBetacoronavirusLymphopeniamedicineHumansCytokinePandemicsAgedInflammationBlood Coagulation DisorderBetacoronavirubusiness.industrySARS-CoV-2Biochemistry (medical)Public Health Environmental and Occupational HealthCOVID-19Biochemical biomarkersmedicine.diseaseImmunologyCytokine stormbusinesslaboratoryBiomarkers
researchProduct

Fibrogenesis assessed by serological type III collagen formation identifies patients with progressive liver fibrosis and responders to a potential an…

2016

There are no approved treatments for liver fibrosis. To aid development of antifibrotic therapies, noninvasive biomarkers that can identify patients with progressive fibrosis and that permit monitoring of the response to antifibrotic therapy are much needed. Samples from a phase II antifibrotic trial of the glitazone farglitazar in patients with advanced hepatitis C, with matched follow-up liver biopsies, and from a phase III study of balaglitazone in patients with late-stage Type 2 diabetes (BALLET study) were analyzed for serological Pro-C3 levels in conjunction with other disease parameters. In the farglitazar study, a predefined cutoff value for Pro-C3 as a selection criterion led to t…

Liver CirrhosisMale0301 basic medicineNonalcoholic steatohepatitisPathologymedicine.medical_specialtyPhysiologyLiver fibrosisType 2 diabetesSerology03 medical and health sciencesCollagen formation0302 clinical medicineFibrosisSerum biomarkersPhysiology (medical)Journal ArticlemedicineHumansOxazolesType III collagenHepatologybusiness.industryPatient SelectionGastroenterologyMiddle Agedmedicine.disease3. Good healthCollagen Type III030104 developmental biologyQuinazolinesTyrosineFemaleThiazolidinediones030211 gastroenterology & hepatologybusinessBiomarkersAmerican Journal of Physiology-Gastrointestinal and Liver Physiology
researchProduct

Severe reduction of blood lysosomal acid lipase activity in cryptogenic cirrhosis: A nationwide multicentre cohort study

2017

Background and aims Blood lysosomal acid lipase (LAL) is reduced in non-alcoholic steatohepatitis, which is the major cause of cryptogenic cirrhosis (CC); few data on LAL activity in CC do exist. We investigated LAL activity in a cohort of patients with liver cirrhosis. Methods This is a multicentre cohort study including 274 patients with liver cirrhosis of different aetiology from 19 centres of Internal Medicine, Gastroenterology and Hepatology distributed throughout Italy. Blood LAL activity (nmol/spot/h) was measured with dried blood spot extracts using Lalistat 2. Results Overall, 133 patients had CC, and 141 patients had cirrhosis by other causes (61 viral, 53 alcoholic, 20 alcoholic …

Liver CirrhosisMaleCryptogenic cirrhosis; Liver disease; Lysosomal acid lipase; PathogenesisCirrhosisCryptogenic cirrhosisCryptogenic cirrhosis; Liver disease; Lysosomal acid lipase; Pathogenesis; Cardiology and Cardiovascular MedicineComorbidityPathogenesisLysosonal acid lipase; non-alcoolic fatty liver disease; cirrhosis030204 cardiovascular system & hematologyGastroenterologyLiver disease0302 clinical medicineModel for End-Stage Liver DiseasePathogenesiRisk FactorsPrevalenceProspective cohort studyMultivariate AnalysiSettore MED/12 - GastroenterologiaMiddle AgedItalyCohortLinear Model030211 gastroenterology & hepatologyFemaleCardiology and Cardiovascular MedicineLiver diseaseHumanmedicine.medical_specialtyLiver CirrhosiDown-Regulation03 medical and health sciencesInternal medicineCryptogenic cirrhosis; Liver disease; Lysosomal acid lipase; Pathogenesis; Aged; Biomarkers; Chi-Square Distribution; Comorbidity; Cross-Sectional Studies; Down-Regulation; Dried Blood Spot Testing; Female; Humans; Italy; Linear Models; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Platelet Count; Prevalence; Risk Factors; Sterol EsterasemedicineLysosonal acid lipaseHumansnon-alcoolic fatty liver diseaseAgedCross-Sectional StudieChi-Square Distributionbusiness.industryPlatelet CountcirrhosisRisk FactorBiomarkerCholesterol ester storage diseaseHepatologySterol Esterasemedicine.diseaseCross-Sectional StudiesMultivariate AnalysisLysosomal acid lipaseLinear ModelsDried Blood Spot TestingSteatohepatitisbusinessCryptogenic cirrhosiBiomarkers
researchProduct

Association Between Serum Levels of Neurofilament Light Chains and Minimal Hepatic Encephalopathy in Patients With Liver Cirrhosis.

2021

INTRODUCTION: Serum biomarkers for the diagnosis of minimal hepatic encephalopathy (MHE) in patients with liver cirrhosis would be desirable. In this proof-of-concept study, we investigated the association between MHE and serum levels of neurofilament light chains (sNfL) in patients with liver cirrhosis. METHODS: sNfL were studied in patients with liver cirrhosis (with or without MHE) and controls (patients with ischemic stroke, transitory ischemic attack, and healthy individuals). MHE was diagnosed using the Psychometric Hepatic Encephalopathy Score. RESULTS: Patients with MHE showed higher sNfL than patients without MHE and controls. In multivariable analyses, higher sNfL were independent…

Liver CirrhosisMalemedicine.medical_specialtyCirrhosisNeurofilament lightGastroenterologyProof of Concept StudySeverity of Illness IndexSerum biomarkersNeurofilament ProteinsInternal medicineMedicineHumansIn patientHepatic encephalopathyAgedbusiness.industryBrief ReportGastroenterologyArea under the curveMiddle Agedmedicine.diseaseHealthy individualsHepatic EncephalopathyIschemic strokeFemalebusinesshuman activitiesBiomarkersClinical and translational gastroenterology
researchProduct

Spike-in SILAC proteomic approach reveals the vitronectin as an early molecular signature of liver fibrosis in hepatitis C infections with hepatic ir…

2014

Hepatitis C virus (HCV)-induced iron overload has been shown to promote liver fibrosis, steatosis, and hepatocellular carcinoma. The zonal-restricted histological distribution of pathological iron deposits has hampered the attempt to perform large-scale in vivo molecular investigations on the comorbidity between iron and HCV. Diagnostic and prognostic markers are not yet available to assess iron overload-induced liver fibrogenesis and progression in HCV infections. Here, by means of Spike-in SILAC proteomic approach, we first unveiled a specific membrane protein expression signature of HCV cell cultures in the presence of iron overload. Computational analysis of proteomic dataset highlighte…

Liver CirrhosisProteomicshepatitis C virusMaleMESH: Isotope LabelingHSCmedicine.disease_causeBiochemistry0302 clinical medicineFibrosisMESH: Up-RegulationMembrane Proteinhepatic stellate cellliver fibrosishepatic iron overload0303 health sciencesbiologyMESH: ProteomicsMedicine (all)hepatocellular carcinomaBiomedicine; hepatitis c infection; liver fibrosis; hepatic iron overload; vitronectinHepatitis C[SDV.BIBS]Life Sciences [q-bio]/Quantitative Methods [q-bio.QM]Hepatitis CUp-Regulation3. Good healthcell culture-derived HCVIsotope Labeling030220 oncology & carcinogenesisHepatocellular carcinomaBiomedicine; Hepatic iron overload; Hepatitis C infection; Liver fibrosis; Vitronectin; Biomarkers; Cell Line; Hepatitis C; Humans; Iron Overload; Isotope Labeling; Liver Cirrhosis; Male; Membrane Proteins; Proteomics; Up-Regulation; Vitronectin; Molecular Biology; Biochemistry; Medicine (all)HCV[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/VirologyBiomarker (medicine)VitronectinMESH: Membrane ProteinsMESH: Liver CirrhosisHumanIron OverloadLiver CirrhosiHepatitis C virusvitronectinhepatitis c infectionCell LineMESH: Iron Overload03 medical and health sciencesmedicineHumans[SDV.BBM]Life Sciences [q-bio]/Biochemistry Molecular BiologyMolecular Biology030304 developmental biologyMESH: Hepatitis CMESH: HumansMESH: Biological MarkersMembrane ProteinsLiver fibrosiProteomicBiomarkermedicine.diseaseMESH: VitronectinMESH: Maledigestive system diseasesMESH: Cell LineBiomedicineBiomedicine / Abbreviations: HCCHCVccImmunologyCancer researchHepatic stellate cellbiology.proteinSteatosisBiomarkersPROTEOMICS
researchProduct

Mass-encoded synthetic biomarkers for multiplexed urinary monitoring of disease.

2011

Biomarkers are becoming increasingly important in the clinical management of complex diseases, yet our ability to discover new biomarkers remains limited by our dependence on endogenous molecules. Here we describe the development of exogenously administered 'synthetic biomarkers' composed of mass-encoded peptides conjugated to nanoparticles that leverage intrinsic features of human disease and physiology for noninvasive urinary monitoring. These protease-sensitive agents perform three functions in vivo: they target sites of disease, sample dysregulated protease activities and emit mass-encoded reporters into host urine for multiplexed detection by mass spectrometry. Using mouse models of li…

Liver CirrhosisUrinary systemBiomedical EngineeringEarly detectionBioengineeringComputational biologyDiseaseBiology010402 general chemistry01 natural sciencesApplied Microbiology and BiotechnologyMass SpectrometryArticle03 medical and health sciencesMiceIn vivoNeoplasmsmedicineAnimalsHumansAmino Acid SequenceBiomarker discovery030304 developmental biologyMonitoring Physiologic0303 health sciencesCancermedicine.disease3. Good health0104 chemical sciencesDisease Models AnimalBlood biomarkersImmunologyMolecular MedicineNanoparticlesCore biopsyBiomarkersBiotechnologyPeptide HydrolasesNature biotechnology
researchProduct